EUVIMEDSkopri EUVIMED
Übersichtsarbeit

Functional autoantibody diseases Basics and treatment related to cardiomyopathies

Niels-Peter Becker, Peter Goettel, Johannes Mueller, Gerd Wallukat, Ingolf Schimke

Frontiers in Bioscience · 2019 · 24 (1) · 48-95

DOI: 10.2741/4709 ↗

At a glance

Übersichtsarbeit in Frontiers in Bioscience, 2019. Written by Niels-Peter Becker and 4 co-authors. Institution: Berlin Cures GmbH Berlin, Knesebeckstrasse 59-61, 10719 Berlin, Germany. Cited 24 times so far (Crossref).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

In the 1970s, autoantibodies directed against G-protein-coupled receptors (GPCR, GPCR-AAB) were discovered. After receptor binding, GPCR-AAB trigger uncontrolled receptor mediated signal cascades, thus producing pathologies. Diseases associated with such functionally active autoantibody type (functional autoantibodies) can be called "functional autoantibody diseases". Here we focus exclusively on GPCR-AAB directed against the GPCR's extracellular loops. The GPCR's role in the pathogenesis and progression is accepted in idiopathic dilated cardiomyopathy and is increasingly considered in diseases such as Chagas' cardiomyopathy, peripartum cardiomyopathy, hypertension, diabetes mellitus and scleroderma and even dementia, complex regional pain syndrome and postural orthostatic tachycardia syndrome. We briefly summarize the mechanistic background of GPCR-AAB induced pathologies, mainly focused on autoantibodies targeting the β1-adrenergic and muscarinic 2 receptors, due to their importance for cardiomyopathies. Furthermore, treatment strategies for "functional autoantibody diseases", such as for GPCR-AAB removal (therapeutic plasma exchange, immunoadsorption) and in vivo GPCR-AAB attack (intravenous IgG treatment, B-cell depletion, GPCR-AAB in vivo binding and neutralization) are critically reflected with respect to their patient benefits focused on but not exclusive to patients with dilated cardiomyopathy.

Subjects

MeSH terms (MEDLINE)

AnimalsAutoantibodiesAutoimmune DiseasesCardiomyopathiesHumansReceptor, Muscarinic M2Receptors, Adrenergic, beta-1Receptors, G-Protein-CoupledSignal Transduction

Substances

AutoantibodiesReceptor, Muscarinic M2Receptors, Adrenergic, beta-1Receptors, G-Protein-Coupled

Authors and institutions

  • Berlin Cures GmbH Berlin, Knesebeckstrasse 59-61, 10719 Berlin, Germany.
  • Berlin Cures GmbH Berlin, Knesebeckstrasse 59-61, 10719 Berlin, Germany, schimke@berlincures.de.

Cite

APA

Becker, N. P., Goettel, P., Mueller, J., Wallukat, G., & Schimke, I. (2019). Functional autoantibody diseases Basics and treatment related to cardiomyopathies. Frontiers in Bioscience, 24(1), 48-95. https://doi.org/10.2741/4709

Vancouver

Becker NP, Goettel P, Mueller J, Wallukat G, Schimke I. Functional autoantibody diseases Basics and treatment related to cardiomyopathies. Frontiers in Bioscience. 2019;24(1):48-95. doi:10.2741/4709

BibTeX
@article{Becker2019,
  author = {Becker, Niels-Peter and Goettel, Peter and Mueller, Johannes and Wallukat, Gerd and Schimke, Ingolf},
  title = {Functional autoantibody diseases Basics and treatment related to cardiomyopathies},
  journal = {Frontiers in Bioscience},
  year = {2019},
  volume = {24},
  number = {1},
  pages = {48--95},
  doi = {10.2741/4709}
}
Start for free →